AI-DRIVEN RNA THERAPEUTICS

Pipeline

Advancing a diversified pipeline of AI-driven therapeutics across high-impact disease areas.

Livera is building a multi-category therapeutic pipeline focused on viral infections, neurological diseases, cardiometabolic diseases, and oncology. Each program is designed to move from AI-assisted discovery toward translational validation, preclinical development, and future clinical partnerships.

RNA • AI • Disease Biology

Pipeline Overview

Viral Infectious Diseases

3 active programs

RNA-directed strategies for chronic viral disease and antigen burden reduction.

Neurological Diseases

3 active programs

AI-designed oligonucleotide programs exploring high-need CNS indications.

Cardiometabolic Diseases

3 active programs

RNA therapeutic programs focused on metabolic liver and cardiovascular biology.

Oncology

3 active programs

Immune-modulating and tumor-targeted RNA programs for solid tumors.

Therapeutic Pipeline

Programs advance from AI-assisted discovery toward translational validation and clinical partnerships.

Viral Infectious Diseases

3 active programs

Program

LVT-VIR-001

Viral Infectious Diseases

Target / Modality

HBV siRNA + immune modulation

Indication

Chronic Hepatitis B

Stage

Discovery to Lead Optimization

Progress

35%

Partnership

Open for collaboration

Program

LVT-VIR-002

Viral Infectious Diseases

Target / Modality

HBV ASO + immune modulation

Indication

Chronic Hepatitis B

Stage

Discovery

Progress

20%

Partnership

Internal discovery

Program

LVT-VIR-003

Viral Infectious Diseases

Target / Modality

HBV Aptamer + immune modulation

Indication

Chronic Hepatitis B

Stage

Early Discovery

Progress

12%

Partnership

Seeking academic collaboration

Neurological Diseases

3 active programs

Program

LVT-NEU-001

Neurological Diseases

Target / Modality

Aβ & Tau Protein

Indication

Alzheimer’s disease

Stage

Discovery

Progress

15%

Partnership

Open for collaboration

Program

LVT-NEU-002

Neurological Diseases

Target / Modality

PrPˢᶜ

Indication

Cognitive impairment

Stage

Early Discovery

Progress

12%

Partnership

Internal discovery

Program

LVT-NEU-003

Neurological Diseases

Target / Modality

Undisclosed CNS program

Indication

Neurological disorder

Stage

Research

Progress

Partnership

Exploratory

Cardiometabolic Diseases

3 active programs

Program

LVT-CVM-001

Cardiometabolic Diseases

Target / Modality

RNA therapeutic

Indication

Metabolic liver disease

Stage

Discovery

Progress

12%

Partnership

Open for collaboration

Program

LVT-CVM-002

Cardiometabolic Diseases

Target / Modality

RNA therapeutic

Indication

Cardiometabolic disorder

Stage

Early Discovery

Progress

10%

Partnership

Internal discovery

Program

LVT-CVM-003

Cardiometabolic Diseases

Target / Modality

Undisclosed metabolic program

Indication

Metabolic disease

Stage

Research

Progress

Partnership

Exploratory

Oncology

3 active programs

Program

LVT-ONC-001

Oncology

Target / Modality

mRNA therapeutic with Immune-modulating

Indication

Solid tumor

Stage

Discovery

Progress

12%

Partnership

Seeking collaboration

Program

LVT-ONC-002

Oncology

Target / Modality

Tumor-targeted oligonucleotide therapeutic

Indication

Oncology

Stage

Early Discovery

Progress

10%

Partnership

Internal discovery

Program

LVT-ONC-003

Oncology

Target / Modality

Undisclosed oncology program

Indication

Solid tumor / immune oncology

Stage

Research

Progress

Partnership

Exploratory